Wegovy
Oral versions of GLP-1s on the horizon
With benefits beyond glucose control for the “new kid on the block” in diabetes management, leading researcher foreshadows oral versions with less side effects New versions of GLP-1 receptor agonists …
Renewed PBS bid for Wegovy
PBAC to consider semaglutide listing for new indication of established CVD with obesity The PBAC will soon consider whether Novo Nordisk’s Wegovy (semaglutide 2.4mg) should be subsidised for Australians with …
‘I’ve seen lots of patients doing that’
People are “microdosing” weight loss drugs mainly due to cost or availability… a pharmacist and a GP who see this frequently share how they respond People are “microdosing” weight loss …
Wegovy’s arrival provides Ozempic alternative for weight management
Supplies of Ozempic (semaglutide) should be prioritised for type 2 diabetes patients the TGA says, as sponsor Novo Nordisk, launches its Wegovy brand for weight loss Pharmacists and prescribers are …
TGA flags compounded Ozempic safety concerns
Pharmacists are being warned that they could be liable for any adverse outcome patients experience should they supply compounded semaglutide-like products Reports that a telehealth provider plans to make compounded …
Another diabetes drug scarce until end 2024
Eli Lilly’s Trulicity had been been ‘go-to’ replacement for in-demand Ozempic Trulicity, the type-2 diabetes preparation which had been a regular stop-gap option when the much-hyped Ozempic was in short …
FDA approves new ‘King Kong’ weight loss drug
Potential blockbuster dubbed Zepbound to join cousin drug Mounjaro on US market Tirzepatide, Eli Lilly’s GIP and GLP-1 agonist, described by media as “the King Kong of drugs”, has been …
The ‘Ozempic effect’ hits worldwide share market
Whether health industry or junk food business, steamroller popularity of weight loss drug shakes up stock prices The huge success of the new wave of GLP-1 (glucagon-like peptide-1) receptor agonist …
Ozempic diabetes competitor gets PBS knockback
Eli Lilly’s Mounjaro would need “substantial price reduction”, says PBAC Mounjaro, the type-2 diabetes medication that the New York Times recently predicted “’could overshadow Ozempic” has been refused funding via …
Semaglutide cancer and depression risks investigation
Concerns Ozempic ingredient may be related to thyroid cancer and suicide ideation draws attention of EMA Semaglutide, the active ingredient in hyped diabetes and weight loss drug, Ozempic and others, …
Oral semaglutide as effective as injectable
Ozempic/Wegovy sponsor trumpets results of Phase III clinical trial as its halts US ads A trial of an oral version of Novo Nordisk’s obesity and diabetes medication semaglutide, the active …
TGA approves next generation diabetes drug Mounjaro
Will Eli Lilly’s potential blockbuster get the same social media weight-loss attention as shortage plagued Ozempic? The next generation of Type-2 diabetes drugs – and by extension weight-loss drugs – …